Omega-3s and Alzheimer’s
This article was originally published in The Tan Sheet
Executive Summary
Omega-3 fatty acid supplementation may slow cognitive decline in some patients with very mild Alzheimer's disease (AD), according to a study in the October Archives of Neurology. While supplementation of DHA and EPA in patients with mild to moderate AD did not delay the rate of cognitive decline, positive effects were observed in post hoc analyses of a small group of patients with the mildest impairment, Yvonne Freund-Levi, MD, Karolinska Institutet, Stockholm, Sweden, et al., conclude. Findings from the additional analyses "cannot serve as a basis for general recommendations for treatment of AD with dietary DHA-rich fish oil preparations," the researchers stress. Daily for six months, 89 patients took 1.7 g of DHA and 0.6 g of EPA while 85 patients took placebo in the randomized, double-blind, clinical trial. Following this first six-month period, all participants received fatty acid supplementation for an additional half-year period. Participants in the treatment arm received 2.8-fold more DHA than EPA because of data on deficiency of DHA in brains affected with Alzheimer's, the researchers state, noting that many omega-3 supplementation trials favor EPA...
You may also be interested in...
Higher DHA Intake Associated With Reduced Risk Of Dementia – JAMA Study
A higher level of DHA in the blood is associated with a 47% reduction in the risk of developing all-cause dementia, a study in the November Archives of Neurology finds
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.